MCID: WLD002
MIFTS: 51

Waldenstrom Macroglobulinemia malady

Rare diseases, Immune diseases categories
Download this MalaCard

Summaries for Waldenstrom Macroglobulinemia

About this section


Fully expand this MalaCard
NIH Rare Diseases:42 Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. it usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. affected individuals have a high level of an antibody called immunoglobulin m (igm) in their blood, which can cause thickening of the blood (hyperviscosity). although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. other symptoms may include peripheral neuropathy, fever, raynaud's phenomenon, and mental status changes. hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. the cause of the condition is not known but environmental, genetic, and viral factors have been suggested. there have been some reports of familial cases suggesting a genetic predisposition. treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues. last updated: 10/1/2013

MalaCards based summary: Waldenstrom Macroglobulinemia, also known as lymphoplasmacytic lymphoma, is related to cryoglobulinemia and multiple myeloma. An important gene associated with Waldenstrom Macroglobulinemia is HAS1 (hyaluronan synthase 1), and among its related pathways are Malaria and Apoptosis and survival Anti apoptotic TNFs NF kB Bcl 2 pathway. The drugs cyclophosphamide and thalidomide and the compounds blys and abciximab have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and lymph node, and related mouse phenotypes are normal and skeleton.

Aliases & Classifications for Waldenstrom Macroglobulinemia

About this section

Waldenstrom Macroglobulinemia, Aliases & Descriptions:

Name: Waldenstrom Macroglobulinemia 30 42 44 62
Lymphoplasmacytic Lymphoma 42 62
Waldenstrom's Macroglobulinaemia 42
 
Macroglobulinemia of Waldenstrom 42
Waldenstrom's Syndrome 42


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Rare diseases
Anatomical: Immune diseases


Related Diseases for Waldenstrom Macroglobulinemia

About this section

Diseases in the Waldenstrom Macroglobulinemia family:

Macroglobulinemia, Waldenstrom 2 Macroglobulinemia, Waldenstrom 1

Diseases related to Waldenstrom Macroglobulinemia via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 82)
idRelated DiseaseScoreTop Affiliating Genes
1cryoglobulinemia31.1CD40LG
2multiple myeloma30.6CD40, IRF4
3myeloma30.5CD40LG, IGHM, IRF4, CD40
4non-hodgkin lymphoma30.2CD40, MS4A1, IRF4
5chronic lymphocytic leukemia30.1IGHM, ZAP70, MS4A1
6leukemia29.8CD40, CD40LG, IRF4, ZAP70
7malt lymphoma29.6IGHM, IRF4, ZAP70, CD40
8b-cell lymphomas29.4IRF4, ZAP70, MS4A1, IGHM, CD40
9follicular lymphoma29.2CD40, ZAP70, MS4A1, IGHM, IRF4
10macroglobulinemia, waldenstrom, somatic29.2HAS1, IRF4, MS4A1, ZAP70, CD40LG, CD40
11macroglobulinemia11.2
12lymphoplasmacytic lymphoma10.5
13cd40 ligand deficiency10.4CD40LG
14histiocytosis10.3
15aplastic anemia10.3
16hepatitis c10.3
17gamma heavy chain disease10.3
18heavy chain disease10.3
19cryoglobulinemic vasculitis10.2IGHM, CD40LG
20agammaglobulinemia10.2CD40LG, IGHM
21malignant spiradenoma10.2CD40LG, CD40
22diffuse large b-cell lymphoma10.2
23hematologic cancer10.2
24hepatitis10.2
25hypertension10.2
26mantle cell lymphoma10.2
27pulmonary hypertension10.2
28retinal vein occlusion10.2
29central retinal vein occlusion10.2
30poems syndrome10.2
31polycythemia vera10.2
32protein-losing enteropathy10.2
33amyloidosis10.2
34colitis10.2
35hairy cell leukemia10.2
36neuropathy10.2
37pancreatitis10.2
38polycythemia10.2
39retinitis10.2
40eosinophilic colitis10.2
41bruton-type agammaglobulinemia10.2CD40, IGHM
42cd40 deficiency10.2CD40, CD40LG
43blood protein disease10.2CD40LG, CD40
44immunodeficiency with hyper igm type 110.2CD40LG, CD40
45primary immunodeficiency disease10.2CD40, CD40LG
46common variable immunodeficiency10.2CD40, CD40LG
47lupus nephritis10.1CD40LG, CD40
48paroxysmal nocturnal hemoglobinuria10.1
49renal tubular acidosis10.1
50wiskott-aldrich syndrome10.1

Graphical network of the top 20 diseases related to Waldenstrom Macroglobulinemia:



Diseases related to waldenstrom macroglobulinemia

Symptoms for Waldenstrom Macroglobulinemia

About this section

Drugs & Therapeutics for Waldenstrom Macroglobulinemia

About this section

Drug clinical trials:

Search ClinicalTrials for Waldenstrom Macroglobulinemia

Search NIH Clinical Center for Waldenstrom Macroglobulinemia

Inferred drug relations via UMLS62/NDF-RT40:

Cell-based therapeutics:


LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine
Read about Waldenstrom Macroglobulinemia cell therapies at LifeMap Discovery.

Genetic Tests for Waldenstrom Macroglobulinemia

About this section

Anatomical Context for Waldenstrom Macroglobulinemia

About this section

MalaCards organs/tissues related to Waldenstrom Macroglobulinemia:

32
Bone, Bone marrow, Lymph node, Spleen, B cells, Heart, T cells

Animal Models for Waldenstrom Macroglobulinemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Waldenstrom Macroglobulinemia:

36
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00028738.3ZAP70, IGHM, HAS1, CD40
2MP:00053908.0CD40LG, ZAP70, IGHM, CD40
3MP:00053977.1IGHM, CD40, CD40LG, ZAP70, MS4A1, IRF4
4MP:00053877.0IGHM, IRF4, MS4A1, ZAP70, CD40LG, CD40

Publications for Waldenstrom Macroglobulinemia

About this section

Articles related to Waldenstrom Macroglobulinemia:

(show top 50)    (show all 108)
idTitleAuthorsYear
1
Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line. (24189269)
2014
2
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. (24716234)
2014
3
Waldenstrom macroglobulinemia: genetics dictates clinical course. (24786453)
2014
4
Waldenstrom macroglobulinemia presenting as isolated persistent epistaxis: a very rare presentation. (24427564)
2013
5
A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia. (23773449)
2013
6
Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia. (23355206)
2013
7
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. (23861223)
2013
8
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). (24004667)
2013
9
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. (22896002)
2012
10
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. (22976953)
2012
11
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. (21732338)
2012
12
Waldenstrom macroglobulinemia with a durable clinical response to epoetin beta. (22260157)
2012
13
Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual. (22404949)
2012
14
FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. (21521775)
2011
15
Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy. (21350089)
2011
16
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. (21415221)
2011
17
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. (21220746)
2011
18
Successful treatment of eosinophilic colitis by montelukast sodium plus budesonide in a patient with Waldenstrom macroglobulinemia. (21575902)
2011
19
New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. (21519243)
2011
20
The bone marrow microenvironment in waldenstrom macroglobulinemia. (23556094)
2011
21
Targeting the bone marrow in Waldenstrom macroglobulinemia. (22035751)
2011
22
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. (19965685)
2010
23
microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. (20519629)
2010
24
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. (20110419)
2010
25
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. (20142586)
2010
26
High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (20368570)
2010
27
Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. (20673674)
2010
28
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. (20795787)
2010
29
Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. (20181958)
2010
30
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. (19220283)
2009
31
International prognostic scoring system for Waldenstrom macroglobulinemia. (19196866)
2009
32
Simultaneously significant hepatic and mild splenic uptake of Tc-99m MDP resulting from Waldenstrom macroglobulinemia. (19542951)
2009
33
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. (18448868)
2008
34
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. (18703425)
2008
35
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. (18815290)
2008
36
Development of EBV-associated diffuse large B-cell lymphoma in Waldenstrom macroglobulinemia and mantle cell lymphoma. (18608870)
2008
37
Irreversible visual loss and optic nerve dysfunction associated with central retinal vein occlusion in Waldenstrom Macroglobulinemia. (18551947)
2007
38
Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. (17441400)
2007
39
Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemia. (17632262)
2007
40
Proteomic analysis of waldenstrom macroglobulinemia. (17440091)
2007
41
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. (17761832)
2007
42
Analysis of 6q deletion in Waldenstrom macroglobulinemia. (17655703)
2007
43
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. (16304043)
2006
44
Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery. (16317092)
2006
45
Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis. (15611977)
2005
46
Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept. (16210920)
2005
47
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. (15493038)
2004
48
A case of t(8;14) with total and partial trisomy 3 in Waldenstrom macroglobulinemia. (9595048)
1998
49
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. (8093333)
1993
50
Pulmonary manifestations of Waldenstrom macroglobulinemia. (6776807)
1980

Variations for Waldenstrom Macroglobulinemia

About this section

Expression for genes affiliated with Waldenstrom Macroglobulinemia

About this section
Expression patterns in normal tissues for genes affiliated with Waldenstrom Macroglobulinemia

Search GEO for disease gene expression data for Waldenstrom Macroglobulinemia.

Pathways for genes affiliated with Waldenstrom Macroglobulinemia

About this section

Compounds for genes affiliated with Waldenstrom Macroglobulinemia

About this section

Compounds related to Waldenstrom Macroglobulinemia according to GeneCards/GeneDecks:

(show all 25)
idCompoundScoreTop Affiliating Genes
1blys449.8CD40, CD40LG
2abciximab44 1110.8CD40LG, CD40
3clopidogrel44 50 24 1112.8CD40LG, CD40
4mycophenolate mofetil44 50 1111.8CD40, CD40LG
5fenofibrate44 50 1111.8CD40, CD40LG
6ivig449.7CD40LG, CD40
7neopterin449.7CD40LG, CD40
8allergens449.7CD40LG, CD40
9ganglioside449.7CD40LG, CD40
10pravastatin44 50 28 24 1113.6CD40LG, CD40
11biotin44 24 1111.6CD40LG, CD40
12fluorochrome449.5CD40LG, ZAP70
13okt3449.5CD40LG, ZAP70
14atorvastatin44 50 28 24 1113.5CD40, CD40LG
15herbimycin a44 6110.5CD40LG, CD40
16hydrocortisone44 2 61 1112.5CD40, HAS1
17hyaluronic acid44 2410.5HAS1, CD40LG, CD40
18paraffin449.3CD40, CD40LG, MS4A1
19cytidine44 24 1111.0CD40LG, ZAP70, CD40
20genistein44 28 61 2 24 1114.0CD40, CD40LG, ZAP70
21cyclophosphamide44 50 1111.0MS4A1, CD40, ZAP70
22dexamethasone44 50 28 1111.7ZAP70, CD40, CD40LG
23fludarabine44 50 1110.5CD40, CD40LG, ZAP70, MS4A1
24rituximab44 50 1110.5CD40, ZAP70, MS4A1, CD40LG
25adp44 28 2410.4CD40LG, ZAP70, CD40

GO Terms for genes affiliated with Waldenstrom Macroglobulinemia

About this section

Cellular components related to Waldenstrom Macroglobulinemia according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:0098978.9MS4A1, CD40LG, CD40
2integral component of plasma membraneGO:0058878.3HAS1, MS4A1, CD40LG, CD40
3plasma membraneGO:0058867.9HAS1, IGHM, ZAP70, CD40LG, CD40

Biological processes related to Waldenstrom Macroglobulinemia according to GeneCards/GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1regulation of immunoglobulin secretionGO:0510239.6CD40LG, CD40
2positive regulation of endothelial cell apoptotic processGO:20003539.6CD40LG, CD40
3positive regulation of interleukin-12 productionGO:0327359.5CD40, CD40LG
4regulation of immune responseGO:0507769.5CD40, CD40LG
5adaptive immune responseGO:0022509.1ZAP70, IGHM
6B cell proliferationGO:0421009.1CD40, CD40LG, MS4A1
7T cell activationGO:0421108.7IRF4, ZAP70

Molecular functions related to Waldenstrom Macroglobulinemia according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1antigen bindingGO:0038239.5CD40, IGHM

Products for genes affiliated with Waldenstrom Macroglobulinemia

About this section
  • Antibodies
  • Proteins
  • Lysates

Sources for Waldenstrom Macroglobulinemia

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet